Tredje AP fonden Purchases 4,078 Shares of BioMarin Pharmaceutical Inc. $BMRN

Tredje AP fonden raised its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 290,742 shares of the biotechnology company’s stock after acquiring an additional 4,078 shares during the quarter. Tredje AP fonden’s holdings in BioMarin Pharmaceutical were worth $15,982,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of BMRN. Nuveen LLC bought a new position in BioMarin Pharmaceutical during the first quarter valued at $184,475,000. AQR Capital Management LLC grew its holdings in BioMarin Pharmaceutical by 127.9% during the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock valued at $203,987,000 after purchasing an additional 1,642,206 shares during the period. Goldman Sachs Group Inc. grew its holdings in BioMarin Pharmaceutical by 212.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after purchasing an additional 1,083,512 shares during the period. Fuller & Thaler Asset Management Inc. bought a new position in BioMarin Pharmaceutical during the first quarter valued at $59,125,000. Finally, Robeco Institutional Asset Management B.V. grew its holdings in BioMarin Pharmaceutical by 559.8% during the second quarter. Robeco Institutional Asset Management B.V. now owns 641,718 shares of the biotechnology company’s stock valued at $35,275,000 after purchasing an additional 544,457 shares during the period. 98.71% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BMRN shares. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a report on Wednesday, October 8th. Barclays cut their price target on BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating for the company in a report on Tuesday, October 28th. Zacks Research lowered BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, UBS Group raised their price target on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Sixteen equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.70.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN opened at $53.57 on Friday. The firm has a market capitalization of $10.29 billion, a price-to-earnings ratio of 20.14, a P/E/G ratio of 0.68 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a 52-week low of $51.00 and a 52-week high of $73.51. The stock has a fifty day moving average of $54.78 and a 200 day moving average of $57.07. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 4.83.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.